Tumor Purity as an Underlying Key Factor in Glioma

• Published in: Clinical cancer research 2017-10, Vol.23 (20), p.6279-6291
• Main Authors: Zhang, Chuanbao, Cheng, Wen, Ren, Xiufang, Wang, Zheng, Liu, Xing, Li, Guanzhang, Han, Sheng, Jiang, Tao, Wu, Anhua
• Format: Article
• Language: English
• Subjects: Biomarkers, Tumor; Brain; Brain Neoplasms - genetics; Brain Neoplasms - immunology; Brain Neoplasms - mortality; Brain Neoplasms - pathology; Brain tumors; Computational Biology - methods; Databases, Genetic; Dilution; Disease Progression; DNA microarrays; Experimental design; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma - genetics; Glioma - immunology; Glioma - mortality; Glioma - pathology; Glioma cells; Humans; Immune system; Indicators; Leukocytes (neutrophilic); Macrophages; Macrophages - immunology; Macrophages - metabolism; Macrophages - pathology; Medical prognosis; Microglia; Mutation; Neutrophils; Neutrophils - immunology; Neutrophils - metabolism; Neutrophils - pathology; Phenotype; Predictions; Prognosis; Promoter Regions, Genetic; Purity; Reviews; Stromal cells; Stromal Cells - metabolism; Stromal Cells - pathology; Tissues; Tumor Microenvironment - immunology
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-16-2598

Glioma tissues consist of not only glioma cells but also glioma-associated nontumor cells, such as stromal cells and immune cells. These nontumor cells dilute the purity of glioma cells and play important roles in glioma biology. Currently, the implications of variation in glioma purity are not sufficiently clarified. Here, tumor purity was inferred for 2,249 gliomas and 29 normal brain tissues from 5 cohorts. Based on the transcriptomic profiling method, we classified CGGA and TCGA-RNAseq cohorts as the RNAseq set for discovery. Cases from TCGA-microarray, REMBRANDT, and GSE16011 cohorts were grouped as a microarray set for validation. Tissues from the CGGA cohort were reviewed for histopathologic validation. We found that glioma purity was highly associated with major clinical and molecular features. Low purity cases were more likely to be diagnosed as malignant entities and independently correlated with reduced survival time. Integrating glioma purity into prognostic nomogram significantly improved the predictive validity. Moreover, most recognized prognostic indicators were no longer significantly effective under different purity conditions. These results highlighted the clinical importance of glioma purity. Further analyses found distinct genomic patterns associated with glioma purity. Low purity cases were distinguished by enhanced immune phenotypes. Macrophages, microglia, and neutrophils were mutually associated and enriched in low purity gliomas, whereas only macrophages and neutrophils served as robust indicators for poor prognosis. Glioma purity and relevant nontumor cells within microenvironment confer important clinical, genomic, and biological implications, which should be fully valued for precise classification and clinical prediction. .